PROJECT NARRATIVE GBM is an incurable disease associated with invariable recurrence despite aggressive therapy with DNA damaging temozolomide and radiation. The focus of this application is to better understand how two specific proteins (RBBP4/p300) interacts to regulate DNA damage response genes that may contribute to the intractable nature of GBM. Ultimately, these studies may identify novel therapeutic strategy that can significantly enhance the efficacy of chemotherapy and/or radiation.
|Effective start/end date||9/19/20 → 6/30/22|
- National Cancer Institute: $727,858.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.